TRIB: 105% | Trinity Biotech shares are trading higher after the company announced an increase in projected revenue for its TrinScreen HIV to $10 million from $8 million.
ADXN: 62% | Addex Therapeutics shares are trading higher after the company and Indivior selected clinical candidates from their GABAB positive allosteric modulator research collaboration. The company is eligible for up to $330 million on achievement of milestones and royalties.
TCOM 10% | Trip.com Group shares are trading higher following Q2 financial results.
